Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer. Adding Tecentriq ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

Tecentriq received accelerated FDA approval for cisplatin-ineligible mUC patients, based on phase II IMvigor210 trial data showing a 23.5% objective response rate. The IMvigor210 trial included 123 ...

Tecentriq (atezolizumab) is a prescription drug that’s used to treat certain cancers. The drug comes as a solution that your doctor will inject. It’s usually given on a cycle every 2, 3, or 4 weeks.

Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously ...

Roche has been hoping its Tecentriq could put up the kind of life-lengthening numbers in squamous non-small cell lung cancer (NSCLC) that could help it compete with Merck’s Keytruda—but no dice. The ...

Tecentriq, a programmed death-ligand 1 (PD-L1) blocking antibody, is currently approved for the treatment of NSCLC, small cell lung cancer, triple-negative breast cancer, and urothelial carcinoma. For ...

In 2016, the FDA granted accelerated approval to Tecentriq for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response. Following a meeting with ...

SOUTH SAN FRANCISCO, Calif., October 02, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) ...

The FDA’s crackdown on drugs that aren’t meeting approval requirements has now hit Roche. The Swiss pharmaceutical giant announced Monday that it is pulling its blockbuster drug Tecentriq from the U.S ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...